In addition, EphA2 overexpression has been associated with resistance to multiple EGFR-targeted TKIs in other malignancies, where EphA2 blockade with ALW-II-41-27 reversed acquired resistance and re-sensitized tumor cells to erlotinib and afatinib [10]. Here, EPHA2 is linked to neoplasm.